Malignant hyperthermia associated with ryanodine receptor 1 (C7360G) mutation in Quarter Horses

Journal of Veterinary Internal Medicine

Volumn 23, Issue 2, 2009, Pages 329-334

  Aleman, M ^a   Nieto, J E ^a   Magdesian, K G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Death; Equine; Rhabdomyolysis; Skeletal muscle

Indexed keywords

ANIMALIA; EQUIDAE;

DNA; RYANODINE RECEPTOR;

ANIMAL; ANIMAL DISEASE; ARTICLE; CHEMISTRY; CYTOCHEMISTRY; DNA SEQUENCE; FEMALE; GENETICS; HORSE; HORSE DISEASE; MALE; MALIGNANT HYPERTHERMIA; POINT MUTATION; PROSPECTIVE STUDY;

ANIMALS; DNA; FEMALE; HISTOCYTOCHEMISTRY; HORSE DISEASES; HORSES; MALE; MALIGNANT HYPERTHERMIA; POINT MUTATION; PROSPECTIVE STUDIES; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SEQUENCE ANALYSIS, DNA;

EID: 66149090036     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2009.0274.x     Document Type: Article

References (47)

1. Denborough M. Malignant hyperthermia. Lancet 1998;352: 1131-1136.
2. Greenbaum I, Weigl Y, Pras E. The genetic basis of malignant hyperthermia. Isr Med Assoc J 2007;9:39-41.
3. McCarthy TV, Healy JM, Heffron JJ, et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990;343:562-564.
4. Fujii J, Otsu K, Zorzato F, et al. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991;253:448-451.
5. Roberts MC, Mickelson JR, Patterson EE, et al. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1). Anesthesiology 2001;95:716-725.
6. Aleman M, Riehl J, Aldridge BM, et al. Association of a mutation in the ryanodine receptor 1 gene with equine malignant hyperthermia. Muscle Nerve 2004;30:356-365.
7. McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000;15:410-417.
8. Klein LV. A hot horse. Vet Anesth 1975;2:41-42.
9. Klein L, Ailes N, Fackelman GE, et al. Postanesthetic equine myopathy suggestive of malignant hyperthermia. A case report. Vet Surg 1989;18:479-482.
10. Hildebrand SV, Howitt GA. Succinylcholine infusion associated with hyperthermia in ponies anesthetized with halothane.Am J Vet Res 1983;44:2280-2284.
11. Hildebrand SV, Arpin D, Cardinet III G Contracture test and histologic and histochemical analyses of muscle biopsy specimens from horses with exertional rhabdomyolysis. J Am Vet Med Assoc 1990;196:1077-1083.
12. Hildebrand SV, Arpin D, Howitt GA, et al. Muscle biopsy to differentiate normal from suspected malignant hyperthermia horses and ponies. Vet Surg 1988;17:172-173.
13. Manley SV, Kelly AB, Hodgson D. Malignant hyperthermia- like reactions in three anesthetized horses. J Am Vet Med Assoc 1983;183:85-89.
14. Waldron-Mease E, Rosenberg H. Post anesthetic myositis in the horse associated with in vitro malignant hyperthermia susceptibility. Vet Sci Comm 1979;3:45-50.
15. Waldron-Mease E, Klein LV, Rosenberg H, et al. Malignant hyperthermia in a halothane-anesthetized horse. J Am Vet Med Assoc 1981;179:896-898.
16. Aleman M, Brosnan RJ, Williams DC, et al. Malignant hyperthermia in a horse anesthetized with halothane. J Vet Intern Med 2005;19:363-366.
17. Riedesel DH, Hildebrand SV. Unusual response following use of succinylcholine in a horse anesthetized with halothane. J Am Vet Med Assoc 1985;187:507-508.
18. Cornick JL, Seahorn TL, Hartsfield SM. Hyperthermia during isoflurane anaesthesia in a horse with suspected hyperkalemic periodic paralysis. Equine Vet J 1994;26:511-514.
19. Smyth GB. Spinal cord decompression and stabilization of a comminuted axis fracture complicated by intraoperative malignant hyperthermia like reaction in a filly. Aust Equine Vet J 1992;10: 133-136.
20. Zhou H, Jungbluth H, Sewry CA, et al. Molecular mechanisms and phenotypic variation in RyR1-related congenital myopathies. Brain 2007;130:2024-2036.
21. Brandt A, Schleithoff L, Jurkat-Rott K, et al. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: Novel mutations and concordance with the in vitro contracture test. Hum Mol Genet 1999;8:2055-2062.
22. Manning BM, Quane KA, Lynch PJ, et al. Novel mutations at a CpG dinucleotide in the ryanodine receptor in malignant hyperthermia. Hum Mutat 1998;11:45-50.
23. Denborough MA. Heat stroke and malignant hyperthermia. Med J Aust 1982;1:204-205.
24. Gronert GA. Dantrolene in malignant hyperthermia (MH)-susceptible patient with exaggerated exercise stress. Anesthesiology 2000;93:905.
25. Gronert GA, Thompson RL, Onofrio BM. Human malignant hyperthermia: Awake episodes and correction by dantrolene. Anesth Analg 1980;59:377-378.
26. Davis M, Brown R, Dickinson A, et al. Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RyR1 mutation in New Zealand and Australian pedigrees. Br J Anaesth 2002;88:508-515.
27. Wappler F, Fiege M, Steinfath M, et al. Evidence for susceptibility to malignant hyperthermia in patients with exerciseinduced rhabdomyolysis. Anesthesiology 2001;94:95-100.
28. Moslehi R, Langlois S, Yam I, et al. Linkage of malignant hyperthermia and hyperkalemic periodic paralysis to the adult skeletal muscle sodium channel (SCN4A) gene in a large pedigree. Am J Med Genet 1998;76:21-27.
29. Marchant CL, Ellis FR, Halsall PJ, et al. Mutation analysis of two patients with hypokalemic periodic paralysis and suspected malignant hyperthermia. Muscle Nerve 2004;30:114-117.
30. Backstrom L, Kauffman R. The porcine stress syndrome: A review of genetics, environmental factors, and animal well-being implications. Agric Practice 1995;16:24-30.
31. Aleman M. A review of equine muscle disorders. Neuromuscul Disord 2008;18:277-287.
32. McCue ME, Valberg SJ, Miller MB, et al. Glycogen synthase (GYS1) mutation causes a novel skeletal muscle glycogenosis. Genomics 2008;91:458-466.
33. McCue ME, Valberg SJ, Lucio M, et al. Glycogen synthase 1 (GYS1) mutation in diverse breeds with polysaccharide storage myopathy. J Vet Intern Med 2008;22:1228-1233.
34. Aleman M, Watson JL, Williams DC, et al. Myopathy in horses with pituitary pars intermedia dysfunction (Cushing's disease). Neuromuscul Disord 2006;16:737-744.
35. Briskey EJ. Etiological status and associated studies of pale, soft, exudative porcine musculature. Adv Food Res 1964;13:89-178.
36. Topel DG, Bicknell EJ, Preston KS, et al. Porcine stress syndrome. Mod Vet Pract 1968;49:59-60.
37. Wedel DJ, Gammel SA, Milde JH, et al. Delayed onset of malignant hyperthermia induced by isoflurane and desflurane compared with halothane in susceptible swine. Anesthesiology 1993;78: 1138-1144.
38. Ducart A, Adnet P, Renaud B, et al. Malignant hyperthermia during sevoflurane administration. Anesth Analg 1995;80: 609-611.
39. Perkins G, Valberg SJ, Madigan JE, et al. Electrolyte disturbances in foals with severe rhabdomyolysis. J Vet Intern Med 1998;12:173-177.
40. Durham WJ, Aracena-Parks P, Long C, et al. RyR1 Snitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice. Cell 2008;133:53-65.
41. Lewis SS, Valberg SJ, Nielsen IL. Suspected immunemediated myositis in horses. J Vet Intern Med 2007;21:495-503.
42. Ryan JF, Tedeschi LG. Sudden unexplained death in a patient with a family history of malignant hyperthermia. J Clin Anesth 1997;9:66-68.
43. Yang T, Riehl J, Esteve E, et al. Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse. Anesthesiology 2006;105: 1164-1175.
44. Valentine BA. Pathologic findings in equine muscle (excluding polysaccharide storage): A necropsy study. J Vet Diagn Invest 2008;20:572-579.
45. Beech J, Lindborg S, Fletcher JE, et al. Caffeine contractures, twitch characteristics and the threshold for Ca21-induced Ca21 release in skeletal muscle from horses with chronic intermittent rhabdomyolysis. Res Vet Sci 1993;54:110-117.
46. Hegreberg GA, Reed SM. Skeletal muscle changes associated with equine myotonic dystrophy. Acta Neuropathol 1990;80: 426-431.
47. Wohlfart G. Dystrophia myotonica and myotonia congenita: Histopathologic studies with special reference to changes in the muscles. J Neuropathol Exp Neurol 1951;10:109-124.